Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2002

View Archived Issues

Serono offers brief R&D overview at investor conference

Cytomyx and Papworth Hospital enter cardiovascular collaboration

Amgen updates investors at healthcare conference

Aventis discusses strategy for long-term growth in San Francisco

Travatan introduced in the U.K.

Industry leader Pfizer expects growth driven by broad and deep pipeline

Lilly anticipates launch of four NCEs during 2002

Plant extract proves highly effective against melanoma in animals

Topoisomerase inhibitor ER-37328 exerts potent antitumor activity in vitro and in vivo

VaxGen AIDS vaccine induces broad immune response to HIV subtypes

Initiation of phase III trial of Ceplene/IL-2 in metastatic melanoma with liver metastases

Dosing in phase IIA trial of AN-1792 in Alzheimer's disease temporarily suspended

Zimmer and Isto collaborate on Neocartilage allograft tissue development and commercialization

Geographical differences observed in Cidecin comparative phase III trial

CancerVax completes Cell Matrix acquisition

Hydroxyfasudil, a Rho kinase inhibitor with antianginal effects

INGAP in first clinical trial to test islet neogenesis in diabetes patients

Biovitrum describes 11beta-HSD1 inhibitors

More convenient formulation of MS medication cleared by FDA

Merck identifies benzodiazepine derivatives that inhibit Abeta formation

Macrolides for use as immunosuppressants in inflammatory conditions described in Novartis patent

Nippon Shinyaku scientists design tropolone derivatives that inhibit 12-lipoxygenase

3-Phenylpropionic acid derivatives synthesized by Kyorin useful in arteriosclerosis Rx

Ligands for GABA-A receptors designed by Merck team

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...